Author: "C Pennucci" / Publisher: s. karger ag - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"C Pennucci"' showing total 2 results

Start Over Author "C Pennucci" Publisher s. karger ag

Author: G. Gardin, P. Rosso, Domenico Amoroso, Wolfgang Cullmann, Giovanni Bonfiglio, Susanne Wendt, Letizia Lombardini, Orietta Dal Pozzo, Gianfilippo Bertelli, A. Loscos, Edna Almodovar, T. Guido, P. A. Bernabei, H.R. Maurer, Gianluca D'Ippolito, J. Prieto, Silvia Fenigli, Joao da Fonseca, C. Pennucci, Roberto Mattina, Wolfgang Opferkuch, Paolo Pronzato, Ramona Kroschinsky, C. Ramos, Mark Burdette, H Leying, Max Gehrlein, F. Mínguez, S. Barrientos, H.T. Hassan, Pierluigi Rossi Ferrini, Clementina Cocuzza, Ursula Wolf, Tom Bergan, M. Cesana, Yoshio Ueno, G. Gulisano, Hussain Qadri, Walter H. Traub, B.P. Imbimbo, and Dierk Bauer
Subjects: Pharmacology, Infectious Diseases, Oncology, Drug Discovery, Pharmacology (medical), General Medicine
Published: 1991
Full Text: View/download PDF

Author: Gianfilippo Bertelli, Paolo Pronzato, G. Gardin, Domenico Amoroso, C. Pennucci, P. Rosso, and T. Guido
Subjects: Adult, Oncology, medicine.medical_specialty, Cyclophosphamide, Oral chemotherapy, medicine.medical_treatment, Mammary gland, Administration, Oral, Breast Neoplasms, Breast cancer, Oral administration, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Drug Discovery, medicine, Humans, Idarubicin, Pharmacology (medical), Aged, Aged, 80 and over, Pharmacology, Chemotherapy, business.industry, Cancer, General Medicine, Middle Aged, medicine.disease, Infectious Diseases, medicine.anatomical_structure, Female, business, medicine.drug
Abstract: An oral chemotherapy schedule based on idarubicin and cyclophosphamide was evaluated in 31 advanced breast cancer patients. Out of 27 patients evaluable for response, 1 (3.7%) achieved a complete response and 5 (18.5%) a partial response, with an objective response rate of 22.2% (95% confidence limits 8.6-42.3%). The median time to progression was 7 months (range 3-12). Fourteen patients (51.9%) showed a disease stabilization, and 7 progressed (25.9%). Toxicity was mild. Considering the low response rate, but also the advantages of oral chemotherapy and the mild toxicity observed, oral idarubicin plus cyclophosphamide can be considered as a second-choice regimen in advanced breast cancer.
Published: 1991
Full Text: View/download PDF

Books, media, physical & digital resources

Searchworks